OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE
EU CTIS ID: 2025-524573-16-00
What this study is testing
To evaluate the one-year effectiveness of GUS in CD in real-world setting
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with a diagnosis of Crohn's disease according to ECCO guidelines
- Absence of contraindication to guselkumab
- Active disease according to PRO2 (abdominal pain > 1 or stool frequency > 3), and faecal calprotectin > 250 ug/g
- Objective active disease (as defined by endoscopy, MRI or IUS) within ≤ 2 month
- 18 years of age or older at the time of informed consent
- Not currently participating in any interventional research
You likely can't join if
- Previous exposure to an anti-IL23
- Combination of an advanced therapy with guselkumab
- Patient with ostomy
- Pregnant or breastfeeding woman
- Patient with perianal Crohn's disease predominant disease
- Patients under legal protection
See the full eligibility criteria
- Patients with a diagnosis of Crohn's disease according to ECCO guidelines
- Absence of contraindication to guselkumab
- Active disease according to PRO2 (abdominal pain > 1 or stool frequency > 3), and faecal calprotectin > 250 ug/g
- Objective active disease (as defined by endoscopy, MRI or IUS) within ≤ 2 month
- 18 years of age or older at the time of informed consent
- Not currently participating in any interventional research
- Naïve or exposed to one or more advanced therapy
- Previous exposure to an anti-IL23
- Combination of an advanced therapy with guselkumab
- Patient with ostomy
- Pregnant or breastfeeding woman
- Patient with perianal Crohn's disease predominant disease
- Patients under legal protection
The study team makes the final eligibility decision.
Where it's taking place
- France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from EU CTIS. The study team decides eligibility, and your own doctor gives medical advice.